MYO10 is overexpressed in EGFR-overexpressing GBMs52, and GBM mouse models indicate that MYO10 supports malignancy because knockout of MYO10 impairs GBM invasion, slows tumor proliferation, reduces integrin-related signaling and prolongs survival53. Here, EGFR is linked to glioblastoma.